These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12871340)

  • 1. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition.
    Gurbel PA; Bliden KP; Hiatt BL
    J Thromb Haemost; 2003 Jun; 1(6):1319-21. PubMed ID: 12871340
    [No Abstract]   [Full Text] [Related]  

  • 2. Durability of platelet inhibition by clopidogrel.
    Gurbel PA; Bliden KP
    Am J Cardiol; 2003 May; 91(9):1123-5. PubMed ID: 12714161
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.
    Gurbel PA; Malinin AI; Callahan KP; Serebruany VL; O'Connor CM
    Am J Cardiol; 2002 Aug; 90(3):312-5. PubMed ID: 12127620
    [No Abstract]   [Full Text] [Related]  

  • 4. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
    Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
    Fu Q; Yokoyama N; Takada K; Ishikawa S; Isshiki T
    Int Heart J; 2010; 51(5):303-7. PubMed ID: 20966600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
    Neubauer H; Engelhardt A; Krüger JC; Lask S; Börgel J; Mügge A; Endres HG
    J Cardiovasc Pharmacol; 2010 Jul; 56(1):91-7. PubMed ID: 20410834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation.
    Seyfarth HJ; Koksch M; Roethig G; Rother T; Neugebauer A; Klein N; Pfeiffer D
    Am Heart J; 2002 Jan; 143(1):118-23. PubMed ID: 11773921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy.
    Geisler T; Zürn C; Paterok M; Göhring-Frischholz K; Bigalke B; Stellos K; Seizer P; Kraemer BF; Dippon J; May AE; Herdeg C; Gawaz M
    Eur Heart J; 2008 Jul; 29(13):1635-43. PubMed ID: 18503057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
    Hong SJ; Park JY; Kim KA; Ahn CM; Park JS; Kim YH; Shim WJ; Park SM; Lim DS
    Circ J; 2009 Jun; 73(6):1111-8. PubMed ID: 19372620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation.
    Zhang R; Ran HH; Zhu HL; Chen Q
    J Int Med Res; 2010; 38(5):1617-25. PubMed ID: 21309475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Barbou F; Morange PE; Hovasse T; Bonnet JL; Alessi MC
    J Thromb Haemost; 2006 Mar; 4(3):542-9. PubMed ID: 16371119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pattern of platelet response to clopidogrel in Iranian patients after percutaneous coronary intervention.
    Namazi S; Khalili A; Kojuri J; Azarpira N
    J Clin Pharmacol; 2012 Jul; 52(7):1098-105. PubMed ID: 22232732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
    Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Kuroda N; Ooyama M; Kuwabara Y; Nomura F; Komuro I
    Heart Vessels; 2010 Jan; 25(1):41-4. PubMed ID: 20091397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.
    Saw J; Madsen EH; Chan S; Maurer-Spurej E
    J Am Coll Cardiol; 2008 Dec; 52(23):1826-1833. PubMed ID: 19038679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.